A new resource from the Partnership for the U.S. Life Science Ecosystem (PULSE) highlights the unique and fundamental role of mergers and acquisitions (M&A) in driving innovation across America’s biopharmaceutical industry.
This new resource includes key insights from economists at Cornerstone Research in their article “The Impact of Pharmaceutical M&A on Innovation,” on the ways in which M&A can help advance medical innovation by:
- Creating economies of scale and scope;
- Allowing companies of all sizes to combine complementary assets;
- Attracting the investment needed to fund new breakthroughs; and
- Incentivizing research and development and scientific risk-taking.
For America to maintain its global leadership in bringing new breakthrough treatments and cures to patients, policymakers must recognize M&A’s vital role in the ecosystem and the partnerships and progress it supports.